Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intismeran with or without MK-3475A versus placebo after resection for high-risk stage I NSCLC
NL-OMON61251Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of intismeran autogene and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Disease-free survival. Started Jun 2026; status: recruiting.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61251.